Different responses to 5-f luoraouracil in mutagenicity and gene expression between two human lymphoblastoid cell lines with or without TP53 mutation

Acta Medica Okayama

Volumn 66, Issue 2, 2012, Pages 119-129

  Oka, Hiroaki ^a   Ouchida, Mamoru ^b   Kondo, Takuya ^a   Morita, Fumio ^a   Shimizu, Kenji ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Microarray analysis; Tk mutation assays; TP53

Indexed keywords

FLUOROURACIL; PROTEIN P53;

ARTICLE; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MICRONUCLEUS TEST; MUTAGEN TESTING; MUTAGENESIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; FLUOROURACIL; GENE EXPRESSION; GENES, P53; HUMANS; MICRONUCLEUS TESTS; MUTAGENESIS; MUTAGENICITY TESTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864750209     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Branda RF, O'Neill JP, Brooks EM, Trombley LM and Nicklas JA: The effect of folate deficiency on the cytotoxic and mutagenic responses to ethyl methanesulfonate in human lymphoblastoid cell lines that differ in p53 status. Mutat Res (2001) 473: 51-71.
2. Leong-Morgenthaler PM, Op Het Velt C, Jaccaud E and Turesky RJ: Mutagenicity of 2-amino-3-methylimidazo [4, 5-f] quinoline in human lymphoblastoid cells. Carcinogenesis (1998) 19: 1749-1754.
3. Bassi L, Carloni M, Fonti E, Palma de la Pena N, Meschini R and Palitti F: Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lympho blastoid cells treated in vitro. Mutat Res (2002) 499: 163-176.
4. ChuangYY, Chen Q, Brown JP, Sedivy JM and Liber HL: Radia tion-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. Cancer Res (1999) 59: 3073- 3076.
5. Amundson SA, Xia F, Wolfson K and Liber HL: Different cytotoxic and mutagenic responses induced by X-rays in two human lympho blastoid cell lines derived from a single donor. Mutat Res (1993) 286: 233-241.
6. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT and Liber HL: Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res (1995) 55: 12-15.
7. Morris SM: A role for p53 in the frequency and mechanism of mutation. Mutat Res (2002) 511: 45-62.
8. Islaih M, Halstead BW, Kadura IA, Li B, Reid-Hubbard JL, Flick L, Altizer JL, Thom Deahl J, Monteith DK, Newton RK and Watson DE: Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res (2005) 578: 100-116.
9. Zschenker O, Borgmann K, Streichert T, Meier I, Wrona A and Dikomey E: Lymphoblastoid cell lines differing in p53 status show clear differences in basal gene expression with minor changes after irradiation. Radiother Oncol (2006) 80: 236-249.
10. Schwartz JL, Jordan R, Sedita BA, Swenningson MJ, Banath JP and Olive PL: Different sensitivity to cell killing and chromosome mutation induction by gamma rays in two human lymphoblastoid cell lines derived from a single donor: possible role of apoptosis. Mutagenesis (1995) 10: 227-233.
11. Arango D, Corner GA, Wadler S, Catalano PJ and Augenlicht LH: c-myc/p53 interaction determines sensitivity of human colon carci noma cells to 5-fluorouracil in vitro and in vivo. Cancer Res (2001) 61: 4910-4915.
12. Grem JL, Danenberg KD, Behan K, Parr A, Young L, Danenberg PV, Nguyen D, Drake J, Monks A and Allegra CJ: Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydroge- nase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res (2001) 7: 999-1009.
13. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP and Johnston PG: The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res (2002) 62: 2644-2649.
14. Honma M, Hayashi M and Sofuni T: Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53- mutated human lymphoblastoid cells. Mutat Res (1997) 374: 89- 98.
15. Greenwood SK, Armstrong MJ, Hill RB, Bradt CI, Johnson TE, Hilliard CA and Galloway SM: Fewer chromosome aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoi- somerase II inhibitor or alkylating agents in human cells with nor mal compared with mutant p53. Mutat Res (1998) 401: 39-53.
16. Allio T, Donner EM and Preston RJ: A comparison of the roles of p53 mutation and AraC inhibition in the enhancement of bleomycin- induced chromatid aberrations in mouse and human cells. Mutat Res (2000) 447: 227-237.
17. Allio T and Preston RJ: Increased sensitivity to chromatid aberra tion induction by bleomycin and neocarzinostatin results from alter ations in a DNA damage response pathway. Mutat Res (2000) 453: 5-15.
18. Zhang LS, Honma M, Hayashi M, Suzuki T, Matsuoka A and Sofuni T: A comparative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell lines in the in vitro micronucleus test. Mutat Res (1995) 347: 105-115.
19. Piper AA and Fox RM: Biochemical basis for the differential sensi tivity of human T- and B-lymphocyte lines to 5-fluorouracil. Cancer Res (1982) 42: 3753-3760.
20. Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet (1989) 16: 215-237.
21. Thomas DM and Zalcberg JR: 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol (1998)25: 887-895.
22. Yajima N, Kondo K and Morita K: Reverse mutation tests in Salmonella typhimurium and chromosomal aberration tests in mam malian cells in culture on fluorinated pyrimidine derivatives. Mutat Res (1981) 88: 241-254.
23. Ohuchida A, Furukawa A, Yoshida J, Watanabe M, Aruga F, MiwaY, Shinkawa K and Kinae N: Micronucleus assays on 5-fluo-uracil and 6-mercaptopurine with mouse peripheral blood reticu- locytes. Mutat Res (1992) 278: 139-143.
24. 5-fluorouracil. IARC Monogr Eval Carcinog Risk Chem Hum (1987) Supplement 6: 316-318.
25. Oka H, Ikeda K, Yoshimura H, Ohuchida A and Honma M: Rela tionship between p53 status and 5-fluorouracil sensitivity in 3 cell lines. Mutat Res (2006) 606: 52-60.
26. Qin B, Tanaka R, Ariyama H, Shibata Y, Arita S, Kusaba H, Baba E, Harada M and Nakano S: In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells. Anti-cancer drugs (2006) 17: 439-443.
27. Honma M, Hayashi M, Shimada H, Tanaka N, Wakuri S, Awogi T, Yamamoto KI, Kodani N, Nishi Y, Nakadate M and Sofuni T: Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test. Muta- genesis (1999) 14: 5-22.
28. Matsushima T, Hayashi M, Matsuoka A, Ishidate M, Miura KF, Shimizu H, Suzuki Y, Morimoto K, Ogura H, Mure K, Koshi K and Sofuni T: Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU). Mutagenesis (1999) 14: 569-580.
29. 5-fluorouracil. IARC Monogr Eval Carcinog Risk Chem Hum (1981) 26: 217-235.
30. Ingraham HA, Tseng BY and Goulian M: Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol (1982) 21: 211-216.
31. Curtin NJ, Harris AL and Aherne GW: Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphos-phate accumulation, DNA damage, and growth inhibition followingexposure to CB3717 and dipyridamole. Cancer Res (1991) 51:2346-2352.
32. Ladner RD: The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci (2001) 2: 361-370.
33. Miyazaki I, Kawai T, Harada Y and Moriyasu F: A predictive factor for the response to S-1 plus cisplatin in gastric cancer. World J Gastroenterol (2010) 16: 4575-4582.
34. Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH and Punt CJ: Predictive and prog nostic markers for the outcome of chemotherapy in advanced col- orectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer (2009) 45: 1999-2006.
35. Wu X, Bayle JH, Olson D and Levine AJ: The p53-mdm-2 auto- regulatory feedback loop. Genes Dev (1993) 7: 1126-1132.
36. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM and Pollack A: The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol (2010) 20: 258-266.
37. Manfredi JJ: The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 24: 1580-1589.
38. He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR and Kuang J: Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene (2005) 24: 2929-2943.
39. Niculescu AB, 3rd, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/ M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol (1998) 18: 629-643.
40. 5-fluorouracil. IARC Monogr Eval Carcinog Risk Chem Hum (1987) Supplement 7: 210-211.
41. Honma M: Generation of loss of heterozygosity and its depen dency on p53 status in human lymphoblastoid cells. Environ Mol Mutagen(2005)45: 162-176.
42. Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, Yasuda T, Matsuyama J, Mori M and Doki Y: p53g enotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg oncol (2010) 17: 634-642.